Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Pharmacokinetics and Pharmacodynamics of the Novel SGLT2 Inhibitor Ipragliflozin
Authors
Keywords
Metformin, Pioglitazone, Sitagliptin, Glimepiride, Severe Renal Impairment
Journal
CLINICAL PHARMACOKINETICS
Volume 53, Issue 11, Pages 975-988
Publisher
Springer Nature
Online
2014-10-14
DOI
10.1007/s40262-014-0180-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus
- (2014) André J. Scheen CLINICAL PHARMACOKINETICS
- Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study
- (2014) A. Kashiwagi et al. DIABETES OBESITY & METABOLISM
- Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study
- (2014) Takeshi Kadokura et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effect of Ipragliflozin (ASP1941), a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects
- (2013) Stephan A. Veltkamp et al. CLINICAL DRUG INVESTIGATION
- The Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Ipragliflozin, a Novel Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor
- (2013) Wenhui Zhang et al. CLINICAL DRUG INVESTIGATION
- Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2
- (2013) Sreeneeranj Kasichayanula et al. CLINICAL PHARMACOKINETICS
- Ipragliflozin Does Not Prolong QTc Interval in Healthy Male and Female Subjects: A Phase I Study
- (2013) Wenhui Zhang et al. CLINICAL THERAPEUTICS
- Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
- (2013) M. A. Abdul-Ghani et al. DIABETES
- Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES CARE
- Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
- (2013) Atsunori Kashiwagi et al. Journal of Diabetes Investigation
- Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
- (2012) Masakazu Imamura et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Combination Treatment With Ipragliflozin and Metformin: A Randomized, Double-Blind, Placebo-Controlled Study in Patients With Type 2 Diabetes Mellitus
- (2012) Stephan A. Veltkamp et al. CLINICAL THERAPEUTICS
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2012) S. E. Inzucchi et al. DIABETES CARE
- No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects
- (2012) R. A. Smulders et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study
- (2012) J. P. H. Wilding et al. DIABETES OBESITY & METABOLISM
- Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus
- (2011) Sherwyn L. Schwartz et al. Diabetes Technology & Therapeutics
- Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
- (2011) Atsuo Tahara et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Revised Equations for Estimated GFR From Serum Creatinine in Japan
- (2009) Seiichi Matsuo et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Global estimates of the prevalence of diabetes for 2010 and 2030
- (2009) J.E. Shaw et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus
- (2009) Sunil Nair et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications
- (2009) George L. Bakris et al. KIDNEY INTERNATIONAL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now